These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 7235684)

  • 21. In vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatis.
    Roblin PM; Hammerschlag MR
    Int J Antimicrob Agents; 2000 Sep; 16(1):61-3. PubMed ID: 11185415
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro evaluation of CP-62,993, erythromycin, clindamycin, and tetracycline against Chlamydia trachomatis.
    Walsh M; Kappus EW; Quinn TC
    Antimicrob Agents Chemother; 1987 May; 31(5):811-2. PubMed ID: 3038010
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activity of spiramycin against chlamydia, in vitro and in vivo.
    Orfila J; Haider F; Thomas D
    J Antimicrob Chemother; 1988 Jul; 22 Suppl B():73-6. PubMed ID: 3182449
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative in vitro activity of A-56268 (TE-031) against gram-positive and gram-negative bacteria and Chlamydia trachomatis.
    Benson C; Segreti J; Kessler H; Hines D; Goodman L; Kaplan R; Trenholme G
    Eur J Clin Microbiol; 1987 Apr; 6(2):173-8. PubMed ID: 2954818
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rosaramicin and tetracycline treatment in Chlamydia trachomatis-positive and -negative nongonococcal urethritis.
    Juvakoski T; Allgulander C; Lassus A
    Sex Transm Dis; 1981; 8(1):12-5. PubMed ID: 7221804
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro activity of rufloxacin against Listeria monocytogenes, Legionella pneumophila, and Chlamydia trachomatis.
    Furneri PM; Bazzano M; Campo L; Cesana M; Tempera G
    Chemotherapy; 1994; 40(2):104-8. PubMed ID: 8131632
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibitory and lethal activities of rosaramicin, erythromycin, and clindamycin against Campylobacter fetus subsp jejuni and intestinalis.
    Smith JA; Isaac-Renton JL; Jellett JF; Chow AW; Ngui-Yen J
    Am J Vet Res; 1983 Aug; 44(8):1605-6. PubMed ID: 6625312
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In-vitro activity of dirithromycin against Chlamydia pneumoniae.
    Roblin PM; Kutlin A; Sokolovskaya N; Hammerschlag MR
    J Antimicrob Chemother; 1997 May; 39(5):647-9. PubMed ID: 9184366
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Commercially available fluorescein-conjugated monoclonal antibody for determining the in vitro activity of antimicrobial agents against Chlamydia trachomatis.
    Webberley JM; Matthews RS; Andrews JM; Wise R
    Eur J Clin Microbiol; 1987 Oct; 6(5):587-9. PubMed ID: 2449348
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro activity of dirithromycin against Chlamydia trachomatis.
    Segreti J; Kapell KS
    Antimicrob Agents Chemother; 1994 Sep; 38(9):2213-4. PubMed ID: 7811051
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In-vitro activity of fleroxacin against Chlamydia trachomatis.
    Steele-Mortimer O; Meier-Ewert H
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():65-70. PubMed ID: 3144551
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative in-vitro activity of moxifloxacin, minocycline and azithromycin against Chlamydia spp.
    Donati M; Rodrìguez Fermepin M; Olmo A; D'Apote L; Cevenini R
    J Antimicrob Chemother; 1999 Jun; 43(6):825-7. PubMed ID: 10404322
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro activity of rifamycins alone and in combination with other antibiotics against Chlamydia trachomatis.
    Jones RB; Ridgway GL; Boulding S; Hunley KL
    Rev Infect Dis; 1983; 5 Suppl 3():S556-61. PubMed ID: 6635445
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [In vitro and in vivo activity of spiramycine on Chlamydia (author's transl)].
    Orfila J; Haider F; Thomas D
    Pathol Biol (Paris); 1982 Jun; 30(6):449-51. PubMed ID: 7050851
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In-vitro activity of 3-azinomethyl-rifamycin (SPA-S-565) against Chlamydia trachomatis.
    Zanetti S; Usai D; Nonis A; Fadda G
    J Antimicrob Chemother; 1996 Feb; 37(2):357-9. PubMed ID: 8707747
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Bacteriostatic and bactericidal activities of cyclines, macrolides and fluoroquinolones against Chlamydia trachomatis].
    Dailloux M; Villemain P
    Pathol Biol (Paris); 1992 May; 40(5):455-60. PubMed ID: 1495827
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Standardized method for determining antimicrobial susceptibility of strains of Ureaplasma urealyticum and their response to tetracycline, erythromycin, and rosaramicin.
    Robertson JA; Coppola JE; Heisler OR
    Antimicrob Agents Chemother; 1981 Jul; 20(1):53-8. PubMed ID: 7283415
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In-vitro activity of gatifloxacin against Chlamydia trachomatis and Chlamydia pneumoniae.
    Roblin PM; Hammerschlag MR
    J Antimicrob Chemother; 1999 Oct; 44(4):549-51. PubMed ID: 10588319
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High treatment failure rate is better explained by resistance gene detection than by minimum inhibitory concentration in patients with urogenital Chlamydia trachomatis infection.
    Shao L; You C; Cao J; Jiang Y; Liu Y; Liu Q
    Int J Infect Dis; 2020 Jul; 96():121-127. PubMed ID: 32173573
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro susceptibility of Ureaplasma urealyticum to rosaramicin.
    Smith TF
    Antimicrob Agents Chemother; 1979 Jul; 16(1):106-8. PubMed ID: 475368
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.